Coherus BioSciences, Inc. financial data

Symbol
CHRS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
C/O Dennis M. Lanfear, 333 Twin Dolphin Dr, Suite 600, Redwood City, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
BioGenerics, Inc. (to 1/3/2012)
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 125 % -45.2%
Quick Ratio 14.4 % -55.9%
Debt-to-equity -675 % -68.2%
Return On Assets -0.07 % +99.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 115M shares +3.46%
Common Stock, Shares, Outstanding 115M shares +5.59%
Entity Public Float 324M USD -26.9%
Common Stock, Value, Issued 12K USD +9.09%
Weighted Average Number of Shares Outstanding, Basic 115M shares +17.9%
Weighted Average Number of Shares Outstanding, Diluted 115M shares +17.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 98.5M USD -12.2%
Costs and Expenses 443M USD +11.5%
Operating Income (Loss) -138M USD +25.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -450K USD +99.8%
Income Tax Expense (Benefit) -380K USD
Net Income (Loss) Attributable to Parent -450K USD +99.8%
Earnings Per Share, Basic 0.04 USD/shares +78%
Earnings Per Share, Diluted -0.04 USD/shares +98.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 97.7M USD +21.7%
Marketable Securities, Current 14.9M USD -88.4%
Inventory, Net 47.6M USD -28.7%
Assets, Current 369M USD -17%
Property, Plant and Equipment, Net 2.91M USD -52%
Operating Lease, Right-of-Use Asset 5.91M USD +3.9%
Intangible Assets, Net (Excluding Goodwill) 71.7M USD +1108%
Goodwill 943K USD 0%
Other Assets, Noncurrent 7.38M USD -5.7%
Assets 505M USD -13.5%
Accounts Payable, Current 21.9M USD -41%
Employee-related Liabilities, Current 15.8M USD -12.9%
Accrued Liabilities, Current 61M USD -9.16%
Liabilities, Current 296M USD +23.3%
Deferred Income Tax Liabilities, Net 1.1M USD 0%
Operating Lease, Liability, Noncurrent 4.98M USD +37.2%
Other Liabilities, Noncurrent 29.2M USD +730%
Liabilities 593M USD -17.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -275K USD -3.77%
Retained Earnings (Accumulated Deficit) -1.5B USD -0.03%
Stockholders' Equity Attributable to Parent -88M USD +34.2%
Liabilities and Equity 505M USD -13.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -46.8M USD +32%
Net Cash Provided by (Used in) Financing Activities 887K USD -76.7%
Net Cash Provided by (Used in) Investing Activities 203M USD +1057%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 115M shares +5.59%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 157M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 98M USD +21.4%
Deferred Tax Assets, Valuation Allowance 423M USD +25.3%
Deferred Tax Assets, Gross 430M USD +26.4%
Operating Lease, Liability 6.4M USD -5.24%
Payments to Acquire Property, Plant, and Equipment 152K USD -75.3%
Lessee, Operating Lease, Liability, to be Paid 7.94M USD +7.32%
Operating Lease, Liability, Current 1.42M USD -54.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.19M USD -27.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.1M USD -41.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure +50%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.54M USD +138%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.13M USD +416%
Deferred Tax Assets, Operating Loss Carryforwards 170M USD +29.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares
Unrecognized Tax Benefits 17.4M USD +3.44%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.53M USD +424%
Additional Paid in Capital 1.41B USD +3.37%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 1.2M USD
Depreciation, Depletion and Amortization 2.2M USD -50%
Share-based Payment Arrangement, Expense 32.2M USD -31%
Interest Expense 32.4M USD -17.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares